Physiogenex SAS

Physiogenex SAS is a nonclinical contract research organization (CRO) based in Toulouse, France,specializing in metabolic diseases, including obesity, type 2 diabetes, NASH/MASH fibrosis, diabetic nephropathy, inflammation, dyslipidemia, and cardiovascular diseases.
Founded in 2003, the company has more than 20 years of experience providing pharmaceutical and biotechnology companies with services such as drug efficacy evaluation and mechanism-of-action analysis.

Features of Physiogenex SAS’s Contract Services for Non-Clinical Studies

Deep expertise in metabolic diseases

The company offersmetabolic disorders such as NASH, diabetes, and obesity,and has developed highly predictive in-house animal models, including hamster and rat models. These models enable efficacy studies under conditions with strong clinical relevance.
Leveraging extensive experience in the field, the company delivers not only robust datasets but also interpretative reports that provide insights into disease mechanisms and translational relevance.

proprietary CRO consulting to support clients’ drug development strategies.

In addition to experimental services, Physiogenex SAS offersproprietary CRO consulting to support clients’ drug development strategies.These services are designed to reduce development timelines and costs while facilitating successful progression toward market entry. Consulting activities include comprehensive literature reviews and in-depth analysis of compound- and target-related data. Continuous interaction with clients is maintained through regular teleconferences and on-site meetings.

Commitment to GLP-based quality standards

Physiogenex SAS’s quality system isbased on Good Laboratory Practice (GLP) principles.By adhering to established operational policies, the company ensures data consistency, traceability, and reliability. In addition,Physiogenex SAS has implemented a quality management system compliant with ISO 9001:2015 requirements,further reinforcing its commitment to high-quality research standards.

Examples of Disease Models Available at Physiogenex SAS

Physiogenex SAS maintainsa broad portfolio of animal models,The company is doing so.

For example, type 1 diabetic rat models induced by streptozotocin (STZ) are used to evaluate blood glucose control, postprandial glucose responses, and mechanisms of action of test compounds. The company also offers acute liver failure models designed to assess liver regeneration, survival improvement, and biomarker responses, supporting comprehensive evaluation of therapeutic candidates.

Physiogenex SAS Non-Clinical Case Study

Evaluation of postprandial glucose-lowering effects of a specific collagen hydrolysate

Physiogenex SAS evaluated the ability of a specific collagen hydrolysate to suppress postprandial blood glucose elevation. In mouse studies, oral administration significantly improved glucose tolerance in both healthy mice and obese, pre-diabetic models.

In a human clinical study involving 16 healthy adults and individuals with prediabetes, ingestion of 5 g or 10 g of the collagen hydrolysate 30 minutes before meals resulted in an average reduction of postprandial glucose spikes by 40–43%.

These findings suggest thatthe specific collagen hydrolysate may support endogenous GLP-1 activityand contribute to the maintenance of metabolic health.

Physiogenex SAS Company Information

Founded in 2003, Physiogenex SAS provides preclinical CRO services and consulting focused on metabolic diseases. In addition to standard CRO activities, the company acts as a research and development partner, offering customized evaluation models and study designs tailored to client needs.
Physiogenex SAS also provides in vivo preclinical imaging services.